Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
GILD · Nasdaq · Healthcare
Fundamental quality
54
out of 100
Gilead Sciences, Inc. is going through a tough financial stretch: it hasn't been profitable over the last twelve months. On fundamental quality it scores 54 out of 100, profiling it as a company with demanding fundamentals. Its weakest area is its profitability (net margin -10.6%). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Gilead Sciences is a large U.S. biotech. Its historic business is antivirals: it leads HIV treatment and revolutionized the cure for hepatitis C. It's now trying to diversify into oncology to depend less on a single area.
Revenue growth: 3.9%
Net margin: -10.6% · ROE: -27.4%
Net debt/EBITDA: -10.85x · FCF: 42.5%
Source: SEC EDGAR · TTM through 30/06/2026
The score includes +2 for dividend strength: 11 consecutive years of increases. Keeping that streak demands growing cash generation and balance-sheet discipline.
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its profitability drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 24,689 | 123 | 7,518 | 25,405 |
| 2021 | 27,305 | 6,225 | 10,805 | 21,357 |
| 2022 | 27,281 | 4,592 | 8,344 | 19,818 |
| 2023 | 27,116 | 5,665 | 7,421 | 18,902 |
| 2024 | 28,754 | 480 | 10,305 | 16,720 |
| 2025 | 29,443 | 8,510 | 9,456 | 17,372 |
Between 2020 and 2025, revenue went from $24,689M to $29,443M (+19%) and net income went from $123M to $8,510M (+6819%). Meanwhile, its margins have widened (from 0% to 29%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$3.16
per share, yearly
47% of earnings
Payout
11 straight years raising it
Growth
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Gilead Sciences, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Gilead Sciences, Inc. a good company to invest in?
In terms of business quality, Gilead Sciences, Inc. scores 54 out of 100 in our analysis, placing it as a company with demanding fundamentals. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Gilead Sciences, Inc. a profitable company?
Over the last twelve months, no: Gilead Sciences, Inc. posts a negative net margin (-10.6%).
Does Gilead Sciences, Inc. have a lot of debt?
No. Gilead Sciences, Inc. has a net cash position: more cash than debt.
Is Gilead Sciences, Inc. growing?
Its revenue has grown 3.9% annualized in recent years.
Does Gilead Sciences, Inc. generate cash?
Yes. It converts about 42.5% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Zimmer Biomet (ZBH) · Baxter International (BAX) · Cardinal Health (CAH) · Cencora (COR) · Humana (HUM) · Centene (CNC) · see more →
The best Healthcare stocks by our model →
Compare Gilead Sciences, Inc. with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Gilead Sciences, Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.